Overview
Netherlands-based legal psilocybin retreat and training organization offering psychedelic-assisted therapy programs for professionals and individuals. They also train facilitators through accredited certification programs.
Synthesis Institute is a Netherlands-based organization pioneering legal psilocybin-assisted therapy in a clinical and educational setting. Operating from Amsterdam, the company offers psychedelic-assisted therapy programs designed for both professionals seeking personal development and individuals seeking therapeutic benefits. Their core offering combines carefully structured psilocybin experiences with professional facilitation and psychological integration support. By operating within Dutch legal frameworks, Synthesis demonstrates a scalable model for delivering evidence-based psychedelic interventions in a regulated, therapeutic environment.
Synthesis has established itself as a leading facilitator training organization, offering accredited certification programs that prepare therapists and coaches to safely guide psychedelic-assisted therapy sessions. The company has built a growing community of trained facilitators across Europe and internationally, positioning itself at the intersection of clinical practice and professional development. As a bootstrapped operation, Synthesis has achieved significant operational scale and credibility without external venture funding, validating the commercial viability of legal psychedelic services. Their programs have attracted hundreds of professionals and individuals seeking transformation through supervised psilocybin experiences.
Synthesis Institute represents a critical proof-of-concept for the emerging psychedelic neurotechnology industry, demonstrating that legitimate, professional psychedelic-assisted therapy can operate successfully within existing legal frameworks. By establishing robust training standards and professional certification, they are helping to legitimize psychedelics as a therapeutic tool and building the workforce needed for broader clinical adoption. Their success illustrates the regulatory, clinical, and business model innovations necessary for psychedelics to transition from research settings into mainstream therapeutic practice, making them an important reference point for the industry's continued development.
More in Psychedelics
Latest industry news
Synchron Closes $275M Series D to Accelerate Stentrode BCI Commercialization
2026-06-15 ยท Funding
MIT Researchers Demonstrate Real-Time Emotion Decoding via Non-Invasive EEG with 94% Accuracy
2026-06-13 ยท Research
Synchron Launches Stentrode Home Edition, Expanding BCI Access Beyond Clinical Settings
2026-06-11 ยท Product
Synchron Reaches 100-Patient Milestone as Stentrode BCI Moves Toward Pivotal Trial
2026-06-09 ยท Industry
Company details
Category
๐ Psychedelics
Location
Amsterdam, Netherlands
Funding
Bootstrapped
Website
synthesisretreat.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages โ